Transforming Alzheimer's Screening

Recipient of the 2019 ADDF's 

Diagnostics Accelerator award

About

RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer’s disease biomarkers in the eye.

Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.

In a quick eye exam, RetiSpec  opens a window of opportunity for timely and specific therapeutic interventions, so the progression of the disease may be slowed or even prevented. 

RetiSpec’s patented technology harnesses Hyperspectral Imagery in synergy with machine-learning to allow for rapid, simple, and cost-effective identification of Alzheimer’s biomarkers years before the emergence of clinical symptoms. 

RetiSpec is using computer vision and machine-learning algorithms to detect unique signatures of Alzheimer’s biomarkers in a manner of seconds

Team

ELIAV SHAKED, M.SC
CEO & Co-founder
MICHAEL WOOD, PHD
CTO
ADAM GRIBBLE, PHD
Lead Scientist
JARED WESTREICH, M.SC
Data Scientist
CATHERINE BORNBAUM, 
PHD, MBA
Head of Clinical Operations & Partnerships
ROY KIRSHON, MBA
COO & Co-founder
MAÏLIS BIETENHADER, PHD
Ocular Imaging Specialist
2020-07-04%2016.17_edited.jpg
ALON HAZAN, M.SC
Head of AI
 

In The News

Oct 05, 2020

RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer's Disease Detection Technology

"The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec's novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer's Disease at both the symptomatic and pre-symptomatic stages," said Eliav Shaked, CEO of RetiSpec. 

university-of-minnesota_750xx3872-2183-0

October 17, 2018

University of Minnesota collaborates with medical imaging startup RetiSpec 

The University’s collaboration with RetiSpec comes following a successful pilot clinical study demonstrating the capabilities of the technology, involving 31 participants both with and without Alzheimer’s. 

Oct 08, 2019

RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)

Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of ADDF, said, "We believe that RetiSpec's retinal scanner stands out and shows promise as a unique diagnostic tool among a range of technologies in development. The technology has the potential to facilitate early diagnosis, improve the lives of patients and their loved ones and save the healthcare system money and resources. The technology will also be useful in making clinical trials for Alzheimer's disease more efficient."

87.jpg

March 04, 2019

CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada 

The CABHI-funded RetiSpec trial will determine the safety and effectiveness of the technology through human clinical testing, and help spur commercialization of the technology in Ontario and Canada – to get it into the hands of those who need it most.

Sep 24, 2019

An Eye Scan For Alzheimer's? Toronto Memory Program is Looking Into It (CTV NEWS) 

An Eye Scan For Alzheimer's? Toronto Memory Program Is Looking Into It.

Dr. Sharon Cohen discuss the RetiSpec technology and the study conducted at Toronto Memory Program.

July 17, 2018

From the Lab to Life: A Retinal Scanner for Early Detection of Alzheimer’s Disease

Ontario Brain Institute backed RetiSpec to accelerate growth in Ontario, Canada. RetiSpec has developed software and “plug and play” hardware components that can be applied directly to existing retinal cameras readily found in optometrists’ offices.

Partners

1LOGO.jpeg
cropped-CABHI_logo_v10_FNL-LOGO_outlines
GENTEX - logo_blk.png
ontario-brain-institute.png

If you are interested in partnering with RetiSpec,

please contact us at hello@retispec.com

Contact Us

  • Grey LinkedIn Icon
  • Grey Twitter Icon

Toronto, ON, Canada

© 2019 RetiSpec Inc. All rights reserved.